ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

glumetinib

Also written as “Glumetinib”, “Gumarontinib Tablets” and “Glumetinib Tablets”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 2 companies.

Drug pageGlumetinib: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 7, 20198 company-led studies, 4 open or runningNext primary completion: Dec 25, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Haihe Biopharma51 open or runningphase 2since Aug 7, 2019Aug 7, 2017none ahead
CSPC Pharmaceutical Groupits history only33 open or runningphase 3since Feb 11, 2025Jul 18, 2024Dec 25, 2026phase 2 · NCT06525350

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Haihe Biopharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 7, 2017First study: phase 1 study in Advanced Solid TumorFirst studyNCT03466268 · 56 enrolled · China
  2. Feb 9, 2018Phase 1 study in Advanced Solid TumorNCT03457532 · 177 enrolled · China
  3. Aug 7, 2019Phase 2 study in C-Met Exon 14 MutationNCT04270591 · 183 planned · United States, China, Japan
  4. Mar 29, 2020Phase 2 study in Negative T790M Mutation and Met AmplificationNCT04338243 · 70 enrolled · China
  5. Aug 17, 2022Phase 1 study in Healthy VolunteersNCT05507294 · 18 enrolled · China

TargetBeta

MET →read by rule
“An orally bioavailable, small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), ”NCIt, by rule

Other programs on MET

ProgramCompanyFurthest phaseStudies
cabozantinibruleExelixisphase 436
CrizotinibrulePfizerphase 431
telisotuzumab adizutecanAbbViephase 318
zanzalintinibruleExelixisphase 317
amivantamabruleJohnson & Johnsonphase 316
vebreltinibrulebeijing-pearl-biotechnology-limited-liability-companyphase 39
vilzemetkibSino Biopharmaceuticalphase 38
dalmelitinibHansoh Pharmaceutical Groupphase 37
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
HS-20117Hansoh Pharmaceutical Groupphase 33
SHR-1826Jiangsu HengRui Medicinephase 27
pamvatamigruleBetta Pharmaceuticalsphase 25

Studies

All 5 Haihe Biopharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05507294Healthy Volunteers · China1CompletedMay 21, 202118
NCT04338243Negative T790M Mutation and Met Amplification · China2UNKNOWNDec 31, 202070
NCT04270591C-Met Exon 14 Mutation · United States, China, Japan2RecruitingOct 25, 2023183
NCT03457532Advanced Solid Tumor · China1CompletedSep 22, 2023177
NCT03466268Advanced Solid Tumor · China1CompletedJan 9, 202356

How it is read

Names in the registry

  • “Glumetinib”, 4 entries
  • “Gumarontinib Tablets”, 2 entries
  • “Glumetinib Tablets”, 1 entry
  • “Glumetinib tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.